January 11, 2026 (InterContinental San Francisco) — We’re pleased to announce that Jimmy Tan, Director and Head of International Business Development at Akeylink Biotechnology, will speak at the ACCESS ASIA BD Forum @ JPM 2026.
ACCESS ASIA, hosted by YAFO, builds on the success of ACCESS CHINA, expanding Asia’s leading cross-border biotech platform to connect innovators with global pharma, investors, and strategic partners. Taking place on January 11, 2026, at the InterContinental San Francisco, the forum provides a global stage for Asian biotech companies to showcase their innovation, foster partnerships, and explore new business development opportunities. View more information at: https://biotochina.org/
About Akeylink Biotechnology
Akeylink Biotechnology was established in 2021 in Shanghai, China, with a focus on developing novel drugs for treating viral infections and liver-related diseases. Akeylink is a spin-out company from Cosunter Pharmaceutical (广生堂), a publicly listed company on Shenzhen Stock Exchange (ticker symbol: 300436) engaging in development and commercialization of generic drugs.
The company focuses on antiviral and liver disease treatments, with a strategically optimized product pipeline for both short- and long-term growth. Its oral small-molecule drug for COVID-19, Tazovid®, a best-in-class 3CL protease inhibitor, has been approved and launched in China in 2023, contributing to the nation’s pandemic response. Another prime asset of the company, GST-HG141, a novel first-in-class oral HBV capsid assembly modulator (CAM) for the treatment of chronic hepatitis B, has shown excellent efficacy and safety results in Phase 2 clinical trials and has successfully advanced to Phase 3. Additionally, GST-HG131, a first-in-class oral HBsAg inhibitor for the treatment of chronic hepatitis B, has displayed excellent tolerability and safety profile in Phase 1 clinical trial and demonstrated robust efficacy in reducing HBsAg levels in a Phase 2 study. It is currently progressing rapidly into Phase 2B/3 studies as a mono- or combination therapy.
About the speaker
Jimmy serves as Director and Head of International Business Development at Akeylink Biotechnology and Cosunter Pharmaceutical, driving international collaboration of innovative drug candidates across the globe. He has 8+ years of experience in brokering transformative BD deals and driving high-impact pharmaceutical strategies, having orchestrated high-value licensing initiatives that advanced organizational goals and delivered cost-effective outcomes across Oncology, Ophthalmology, and other therapeutic areas.
About ACCESS ASIA BD Forum @ JPM 2026
ACCESS ASIA BD Forum @ JPM is scheduled to be held on January 11, 2026, at the InterContinental San Francisco, alongside the J.P. Morgan Healthcare Conference Week.
This full-day forum will feature keynote speeches, panel discussions, corporate presentations, company showcases, and 1-on-1 partnering meetings connecting Asia’s leading biotech innovators with global pharma, investors, and strategic partners.
Conference Name: ACCESS ASIA BD Forum @ JPM 2026
Date & Venue: January 11, 2026 | InterContinental San Francisco
View more information at: https://biotochina.org/
MORE INFORMATION
Contact Us
Register as an attendee for ACCESS ASIA BD Forum @ JPM:
For more information, please contact:
Wendi Xiang | Wxiang@yafocapital.com
BioToChina.org 